MISSION
To create a world of bionic vision for those who have lost their sight, via best in class bionic vision systems that interface the eye with the brain, and enable the blind to regain greater autonomy and improved quality of daily living.

TECHNOLOGY
PRIMA is a novel Bionic Vision System (BVS), consisting of a wireless miniaturized and scalable sub-retinal photovoltaic implant, a pair of glasses with a mini-camera and digital projector, and pocket computer, intended to compensate for blindness from macular degeneration of the retinal photoreceptor cells (cones and rods).

COMPETITION
Currently no known curative solutions for AMD when the disease has caused severe to profound vision loss, nor are there any established treatments yet that delay or reverse the progression of Dry AMD. Other devices or restorative approaches (gene or cell therapy) are either focused on rare inherited blindness resulting from Retinitis Pigmentosa, or early research stages.

ALLIANCES/PARTNERSHIPS
Stanford University (USA)
Vision Institute (France)
University of Pittsburgh Medical Center (USA)
Moorfields Eye Hospital (UK)

UPCOMING CATALYSTS
Start of clinical study in the US (UPMC Pittsburgh) for Atrophic dry-AMD, with 5 patients feasibility study (Q2 2018)
Completion of enrollment of 5 patients in European feasibility study (Q2 2018)
6-month follow-up data from the 5 implanted patients in Europe (Q4 2018)

MARKET FIGURES (listed companies)
Revenues 2017: 2.535M€
Date of IPO: June 18, 2014
Ticker: PIX
Exchange: Euronext Paris
Currency: EUR
Market cap: 37M€
Price: 2.45€
52-weeks-high: 6.46€
52-weeks-low: 2.14€
Average daily volume: 146,728

LISTED COMPANY

CREATION DATE
2011
PIXIUM VISION

NAME OF THE CEO
Khalid ISHAQUE

ADDRESS
74 Rue du Faubourg Saint-Antoine,
75012 Paris

EMAIL
investors@pixium-vision.com

www.pixium-vision.com

MANAGEMENT TEAM
CEO: Khalid ISHAQUE
CFO: Didier LAURENS
CTO: Guillaume BUC

TARGETED MARKET
Advanced dry form of Age-related
Macular Degeneration dry-AMD, a
large unmet medical need where
there is currently no proven treatment
available on the market

LISTED COMPANY

CREATION DATE
2011

COMPANY SUMMARY
BIO Boston 1x1 meeting

KEY FIGURES

€m | 2016 | 2017 | Growth (%)
---|---|---|---
Revenues | 2.5 | 2.5 | 0%
EBIT | (12.5) | (12.7) | -1.6%
Net Income | (12.4) | (13.5) | -8.1%
Cash Position | 14.2 | 10.5 | |

ANALYST COVERAGE

<table>
<thead>
<tr>
<th>Broker</th>
<th>Date</th>
<th>Reco. (buy/neutral/hold)</th>
<th>Target Price</th>
<th>Potential (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oddo</td>
<td>04/11/2018</td>
<td>Neutral</td>
<td>3.90€</td>
<td>66%</td>
</tr>
<tr>
<td>Gilbert Dupont</td>
<td>04/10/2018</td>
<td>Buy</td>
<td>5.00€</td>
<td>112%</td>
</tr>
<tr>
<td>Edison</td>
<td>03/08/2018</td>
<td>Buy</td>
<td>5.44€</td>
<td>131%</td>
</tr>
<tr>
<td>Average</td>
<td>-</td>
<td>-</td>
<td>4.78€</td>
<td>103%</td>
</tr>
</tbody>
</table>

SHAREHOLDERS (percentage)

- Sofinnova: 19%
- BPIfrance: 17%
- Abingworth: 10%
- Omnes: 7%
- Management / employees: 4%
- Free float: 43%

PIPELINE

PRIMA
- Feasibility clinical study (France) – Atrophic dry-AMD – on going
- Feasibility clinical study (USA) – Atrophic dry-AMD – To start soon (Q2 2018)